Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI-322 Plus Lenvatinib in Extensive Stage Small Cell Lung Cancer
NCT05296603Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Dec 2021
- Primary completion
- Oct 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of simridarlimab in small cell lung cancer (SCLC), sponsored by Hunan Cancer Hospital. Started Dec 2021; status: recruiting.
02
Drugs
simridarlimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05296603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296603.